Puma Biotechnology (NASDAQ:PBYI) Director Troy Edward Wilson Sells 5,000 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Wilson sold 5,000 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $9.10, for a total value of $45,500.00. Following the completion of the sale, the director directly owned 54,750 shares of the company’s stock, valued at $498,225. This represents a 8.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Puma Biotechnology Trading Up 1.5%

Shares of Puma Biotechnology stock opened at $9.39 on Thursday. The company’s fifty day simple moving average is $8.71 and its 200-day simple moving average is $7.65. The company has a market cap of $484.71 million, a price-to-earnings ratio of 18.06 and a beta of 1.24. Puma Biotechnology, Inc. has a 1 year low of $4.30 and a 1 year high of $9.73.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.04 by $0.15. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%. The firm had revenue of $56.50 million during the quarter, compared to analysts’ expectations of $53.00 million. As a group, research analysts forecast that Puma Biotechnology, Inc. will post 0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on PBYI. Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 15th. TD Cowen boosted their price target on Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a research note on Friday, August 7th. Finally, Weiss Ratings raised Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 21st. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat, Puma Biotechnology has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its position in shares of Puma Biotechnology by 244.5% during the 1st quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 3,066 shares during the period. Legal & General Group Plc acquired a new position in Puma Biotechnology during the second quarter worth $35,000. ProShare Advisors LLC acquired a new position in Puma Biotechnology during the fourth quarter worth $60,000. Philadelphia Investment Partners LLC bought a new position in shares of Puma Biotechnology during the second quarter valued at $65,000. Finally, DGS Capital Management LLC bought a new position in shares of Puma Biotechnology during the first quarter valued at $67,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s primary product is NERLYNX (neratinib), an oral tyrosine kinase inhibitor designed to target HER2 and other members of the human epidermal growth factor receptor family.

In the United States, NERLYNX is approved for the extended adjuvant treatment of adults with early-stage HER2-positive breast cancer following postoperative trastuzumab-based therapy.